2Pfaller MA, Messer SA, Hollis RJ, et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and arnphotericin B,against 239 nical isolates of asppergillusspp, and other Filamentous fungi: report from SENTRY antimicrobial surveillance program, 2000 [J]. Antimicrob Agents Chemotherapy,2002,46(4): 1032 -1037.
3Boogaerts M,Winston DJ,Bow EJ,et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in tropenie patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial[J]. Ann Intern Med,2001,135(6) :412-422.
2New Guidelines on Anaemia Management in Patients with Cancer:How Do These Affect Clinical Practice [ J ] ? Gunnar Birgegarda,Carsten Bokemeyerb. a Department of Hematology, University Hospital, Uppsala, Sweden; bUniversity Medical Center, Eppendorf, Department of Haematology and Oncology, Hamburg,Germany, Oncology, 2005, 69 (Suppl2): 17-21.
3Practice HG, Kibbler CC, Prentice AG. Towards a targeted,risk -based, antifungal strategy in neutropenic patients [ J ]. Br J Haematol, 2003, 110:273-284.
4Becker M J, Lugtenburg E J, Coruelissen J J, et al. Galactomannan detection in computerized tomography - based broncho - alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis [ J ] . Br J Haematol, 2003,121 : 448 -457.
5Maertens J, Van Eldere J, Verhaegen J, et al. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients [J]. J Infect Dis, 2002, 186: 1297-1306.
6Menichetti F, Favero AD, Martino P, et al. Traconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo - controlled, double - blind, multicenter trial [ J ]. Clinical Infectious Diseases, 1999, 28, 250-255.
7Meunier -Carpentier F. Symposium on infectious complications of neoplastic disease ( Part 1I), Chemoprophylaxis of fungal infections[J]. American Journal of Medicine, 1984, 76, 652 -656.
8Nguyen MH, Peacock JE, Morris AJ, et al. The changing face of candidemia : emergence of non - Candida albicans species and antifungal resistance[J]. American Journal of Medicine, 1996,100, 617-623.
9Pfaller MA,Messer SA,Hollis RJ,et al.Antifungal activities of posaconazole,ravuconazole,and voriconazole compared to those of itraconazole and amphotericin B,against 239 clinical isolates of asppergillus spp,and other Filamentous fungi:report from SENTRY antimicrobial surveillance program,2000[J].Antimicrob Agents Chemotherapy,2002,46 (4):1032 -1037.
10Kauffman CA,Carrer PL.Antifungal angents in the 1990s.Current status and future developments[J].Drugs,1997,53(4):539 -549.
3Gimis SB,Chapuis F,Decullier E,et al.Adverse effets of antifungal therapies in invasive fungal infections:review and metaaIIalysis[J].Eur J Clin Microbiol Infect Dis,2005,24:119-130.
4Colombo AL,Perfeet J,DiNubile M,et al.Global distribution and out-comes for Candida species causing invasive candidiasis:result- sfrom an-international randomized double-blind study of caspo- fungin versus am-photericin B for the treatment of invasive cand- idiasis[J].Eur J Clin Microbiol Infect Dis,2003,22(4):470-474.
6Tumbarello M, Pesteraro B, Trecariehi EM, et al.Biofilm production by Candida species and inadequate antifungal therapy predictors ofmortality for patients with candidemia[J].JClin Micmbiol, 2007,45- 50.
7R, Abizanda Campos,S, Altaba Tena,A,Belenguer Muncharaz,et al. Study of post-ICU mortality during 4 years (2006-2009). Analysis of the factors related to death in the ward after discharge from the ICU[J]. Medicina intensiva / Sociedad Espa?ola de Medicina Intensiva y Unidades Coronarias, 2011,35(3): 150-156.
